Recent developments include a $110 million offering to advance MICVO, leadership changes with a new CEO and Chairman, and ongoing clinical data updates supporting MICVO's development.

• In September 2026, Pyxis priced a $110 million offering with potential proceeds of $282 million to advance development of its lead cancer drug MICVO [N1].
• The company confirmed Thomas Civikas as CEO and Chairman in September 2026, following an interim CEO appointment earlier in the year [N4].
• Positive preliminary Phase 1 monotherapy data in 2L+ R/M HNSCC were reported, showing objective response rates around 46% and disease control rates of 92% [N5].
• Ongoing Phase 1/2 combination study with pembrolizumab showed a 71% objective response rate and 100% disease control rate in a small cohort of R/M HNSCC patients [N2].
• Pyxis continues to enroll and treat patients in monotherapy dose expansion cohorts across the US, EU, and other countries [N3].
• The company announced an interim CEO appointment and leadership transition in early 2026 to support strategic focus and program continuity [N6].

The company's lead candidate MICVO has demonstrated promising preliminary clinical activity in heavily pre-treated R/M HNSCC patients, including objective responses and disease control. The combination with pembrolizumab shows enhanced response rates and tolerability, supporting further clinical development. Successful completion of pivotal trials and regulatory approvals could establish MICVO as a novel treatment option addressing significant unmet needs in head and neck cancer. Strategic collaborations and capital raises provide financial resources to advance development and commercialization efforts.

Clinical development risks include potential safety or efficacy issues emerging in larger or later-stage trials, which could delay or limit regulatory approvals. The ADC modality faces competition from other targeted therapies and immuno-oncology agents in head and neck cancer. Financial constraints or inability to secure sufficient funding or partnerships could impact the company's ability to sustain operations and complete clinical programs. Market adoption risks exist given the complexity of treatment paradigms and reimbursement environments globally.

Pyxis Oncology's moat is centered on its proprietary ADC technology targeting the tumor extracellular matrix component EDB+FN, which is selectively expressed in tumors but minimally in normal tissues. This novel targeting approach, combined with a unique three-pronged mechanism of action, differentiates MICVO from conventional ADCs that target cell surface antigens. The company's Flexible Antibody Conjugation Technology (FACT) platform and APXiMAB antibody discovery platform further support its biologics development capabilities. Clinical progress and intellectual property protection around MICVO and its technology platforms contribute to potential competitive advantages in the oncology ADC space.

• Clinical Development Risk: The safety and efficacy profile of MICVO in larger patient populations and later-stage trials may differ from preliminary data, potentially impacting regulatory approvals and commercialization.
• Financial Risk: The company relies on capital raises and strategic collaborations to fund operations; insufficient funding could delay development programs.
• Competitive Risk: MICVO competes in a crowded oncology market with other ADCs and immunotherapies targeting head and neck cancers, which may affect market penetration.
• Regulatory and Market Access Risk: Regulatory approvals and reimbursement decisions in different regions may affect the commercial viability of MICVO.

• Pyxis Oncology is a clinical-stage oncology company focused on developing therapies for solid tumors, with an immediate focus on recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC).
• The lead product candidate is micvotabart pelidotin (MICVO), an investigational antibody-drug conjugate (ADC) targeting extradomain-B of fibronectin (EDB+FN) in the tumor extracellular matrix.
• MICVO's mechanism of action involves binding to EDB+FN in the tumor microenvironment, releasing a microtubule inhibitor payload that kills cancer cells directly, induces a bystander effect, and triggers immunogenic cell death.
• MICVO is being studied as monotherapy and in combination with pembrolizumab (KEYTRUDA) in clinical trials for R/M HNSCC and other solid tumors.
• Phase 1 monotherapy dose escalation and expansion studies have shown positive preliminary efficacy signals, including objective response rates around 46-50% in heavily pre-treated R/M HNSCC patients.
• Preliminary safety data indicate MICVO is generally well tolerated with manageable treatment-related adverse events; dosing modifications are being evaluated to optimize benefit-risk profile.
• A Phase 1/2 combination study with pembrolizumab is ongoing, with preliminary data showing a 71% objective response rate and 100% disease control rate in a small cohort of R/M HNSCC patients.
• Pyxis has completed enrollment of approximately 40 patients in the Phase 1 monotherapy dose expansion study and is actively treating patients in multiple cohorts across the US, EU, and other countries.
• The company has obtained FDA feedback on a planned pivotal monotherapy study in 2L+ R/M HNSCC and is conducting dose escalation to identify the recommended Phase 2 dose for combination therapy.
• Pyxis Oncology was founded in 2018 and has a multidisciplinary team with experience across oncology R&D and commercialization.
• The company aims to build a leading ADC oncology company, focusing on MICVO development for significant unmet needs in R/M HNSCC.
• Pyxis seeks strategic collaborations to support capital-efficient development and maximize value from its intellectual property and biologics technology platforms.
• Head and neck squamous cell carcinoma is a common cancer with high unmet medical need, especially in the recurrent/metastatic setting where survival rates are low and treatment options limited.
• The standard of care for R/M HNSCC involves pembrolizumab monotherapy or combination with chemotherapy, but options beyond first line are limited and outcomes remain poor.
• Financial snapshot as of 2026-09-30 shows cash and equivalents of $3.86 million, short-term investments of $51.7 million, current assets of $59.1 million, current liabilities of $19.9 million, with a current ratio of 2.96 and cash ratio of 2.79.
• Net loss for the nine months ended 2026-09-30 was $19.98 million, with basic and diluted EPS of -$0.24 per share.
• In September 2026, Pyxis priced a $110 million offering with potential proceeds of $282 million to advance MICVO development.
• Leadership changes include confirmation of Thomas Civikas as CEO and Chairman in September 2026, following an interim CEO appointment earlier in 2026.